ePrints

Inhibition of poly(ADP-ribose) polymerase in cancer

Lookup NU author(s): Professor Ruth Plummer

Downloads

• Published version [.pdf]

Abstract

Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited. © 2006 Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Plummer ER

Publication type: Review

Publication status: Published

Journal: Current Opinion in Pharmacology

Year: 2006

Volume: 6

Issue: 4

Pages: 364-368

Print publication date: 01/08/2006

ISSN (print): 1471-4892

ISSN (electronic):

URL: http://dx.doi.org/10.1016/j.coph.2006.02.004

DOI: 10.1016/j.coph.2006.02.004

Share